Prominent Scientist Switches Labs, Sparking Administrative Fireworks

Philadelphia's reputation for brotherly love suffers after Carlo Croce decides to remove himself and his staff from Fels Institute Cell lines have died. At least one grant deadline will be missed. Scientists speak with bitterness and resentment about their colleagues, and an entire university's commitment to science is being called into question. Things are far from business as usual at Temple University's Fels Institute in Philadelphia, where earlier this year institute director Carlo Croce an

Written bySusan L-J Dickinson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

It is not unusual for a scientist to change institutions. Many do so several times in a career, as opportunities for expanded research, career advancement, and collaboration with prestigious colleagues present themselves. But a move of this magnitude is far from ordinary, as are the ramifications.

Whether it is the prominence of the players involved (Croce, among other honors, holds an National Institutes of Health Outstanding Investigator Award, is editor-in-chief of Cancer Research, and last month announced his discovery of a gene that may be a determining factor in lung cancer), the proximity of the two institutions, or, as Joseph Gonnella, senior vice president of academic affairs and dean of Jefferson Medical College suggests, "the personalities of the people involved," things have turned ugly. Allegations of underhandedness, obstruction of science, and outright lying abound, and it is difficult to find anyone objective about the situation. Worst of all, science appears ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies